Signant Health has announced new audit trail reviewing and reporting functionality for its electronic clinical outcome assessment (eCOA) and remote sensor platform, TrialMax. This new functionality enables authorized personnel to access and explore key audit trail data through interactive reports and dashboards in just a few clicks. The efficiencies are realized through TrialMax’s ability to track user actions and inputs in real-time, creating a behind the scenes audit trail as users interact with the tool, and through leveraging Signant Health’s enterprise analytics platform.
Signant Health developed TrialMax’s latest audit features in consultation with users and clients responsible for clinical oversight and data management in order to ensure compliance with data integrity guidance and definitions from the FDA, EMA and MHRA. These latest features provide TrialMax users with:
This update comes in response to the ever-increasing demand from regulatory bodies on life science companies to put quality systems in place to ensure generation of high-integrity data for accurate drug evaluation. Enabling the detailed inspection of audit trail data is a regulatory compliance requirement, with audit trail deficiencies cited in a growing number of regulatory inspections.
“The proliferation of home-based remote sensors, eCOA, and other sources of patient data have increased the volume and variety of data captured in today’s trials, making data integrity monitoring more cumbersome than ever before”, comments Rauha Tulkki-Wilke, Senior Vice President, Product Management, Signant Health. “The TrialMax platform now offers enhanced audit trail reporting capabilities that enable sponsors and sites to fulfill regulatory and GCP requirements by inspecting the underlying audit history to ensure data integrity-made easy through the interactive reporting tools provided through TrialMax. This is a critical element in establishing the traceability and reliability of an electronic record.”
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.